CDMO vs. In-House Medical Device Manufacturing: A Strategic Comparison for 2026
The assumption that internalizing every phase of production guarantees superior oversight is rapidly becoming a strategic liability. As the FDA’s…
The Strategic Advantage of Outsourcing Medical Device Production in 2026
In 2026, approximately 60% of Good Manufacturing Practice (GMP) inspection findings are linked to data integrity and documentation control issues….
Comprehensive Medical Device Contract Manufacturing Services for Global MedTech
With the global market for medical device contract manufacturing services projected to reach USD 93.5 billion in 2026, the pressure on MedTech OEMs…